The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results.

Glynis Ablon

RCT Journal of cosmetic dermatology 2025 1 اقتباسات

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D41319217'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

نوع الدراسة: randomized controlled trial
حجم العينة: 60
المدة: 12.9 weeks

التدخل: The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: Proprietary saw palmetto (Serenoa repens) bioactive fatty acids extract, 1 oral dose daily for 90 da
المقارن: Placebo
اتجاه التأثير: Positive
خطر التحيز: Low

Abstract

BACKGROUND: Hair loss is a global concern for both men and women. AIMS: This study assessed the efficacy and safety of a proprietary extract of bioactive fatty acids from saw palmetto for treating self-perceived thinning hair in healthy adult male and female subjects. METHODS: In this 6-month, randomized, double-blind, placebo-controlled study, subjects were randomized to receive active treatment (n = 40) or placebo (n = 20). Half of the enrolled subjects were female. Subjects took one oral dose of their assigned treatment daily. Assessments were performed at baseline, Day 56 and Day 90. Preliminary 90-day results are presented here. PATIENTS/METHODS: The active group showed significant improvement in terminal hair count from baseline in anterior (p < 0.0007) and posterior (p < 0.0005) areas. Compared to placebo, the improvement was also significant in the anterior (p < 0.05) and posterior (p < 0.03) areas. Anterior vellus hair count improved significantly versus baseline (p < 0.0005) and placebo (p < 0.01). Posterior vellus hair count showed significant within-group growth (p < 0.05). Total hair count was significantly greater than baseline for anterior (p < 0.001) and posterior (p < 0.0005) and significantly greater for anterior (p < 0.005) and posterior (p < 0.05) compared to placebo. Total terminal hair counts improved 7-fold, and total hair count improved 12-fold compared to placebo. A significant reduction in hair shedding was observed in the active group versus baseline (p < 0.05). No meaningful improvements were observed in the placebo group, and no adverse events were reported. CONCLUSION: These preliminary results indicate the daily administration of a proprietary saw palmetto (Serenoa repens) extract safely and effectively promotes hair growth in men and women with self-perceived thinning hair. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT06920758.

Full Text

PDF

Loading PDF...

Figures

FIGURE 1

Study design or participant flow for the clinical trial assessing a proprietary saw palmetto bioactive fatty acids extract for promoting hair growth in adults with self-perceived thinning hair.

flowchart

FIGURE 2

Hair growth outcome measures showing improvements in hair density or shedding rates in participants receiving the saw palmetto extract compared with baseline or control.

chart

Tables

TABLE 1

	Active	Placebo
	n = 40	n = 20
Mean age, years (SD)	50.6 (9.6)	48.9 (10.9)
Median age, years (min, max)	55.0 (28, 63)	50.5 (29, 63)
Race, n (%)	n = 40	n = 20
White	36 (90)	14 (70)
Black	1 (2.5)	1 (5)
Asian	1 (2.5)	2 (10)
American Indian/Alaskan Native	—	2 (10)
Native Hawaiian/Pacific Islander	—	1 (5)
Mixed race	2 (5)	—
Ethnicity, n (%)	n = 40	n = 20
Hispanic/Latino	32 (80)	15 (75)
Non‐Hispanic/Latins	8 (20)	5 (25)
Fitzpatrick skin type	n = 40	n = 20
Type I	6 (15)	5 (25)
Type II	14 (35)	4 (20)
Type III	12 (30)	5 (25)
Type IV	6 (15)	5 (25)
Type V	2 (5)	—
Type VI	—	1 (5)
Norwood classification scale (male subjects), n (%)	n = 20	n = 10
II	1 (5)	1 (10)
III	8 (40)	7 (70)
III Vertex	11 (55)	2 (20)
Savin pictorial scale (female subjects), n (%)	n = 20	n = 10
1–2	15 (75)	7 (70)
1–3	5 (25)	3 (30)

TABLE 2

	Active (n = 40)			Placebo (n = 20)
	Day 0	Day 90	Change	Day 0	Day 90	Change
Anterior terminal hair counts
Mean (SD)	132.9 (29.2)	144.2 (32.4)	+11.3 (19.4)^a,b	131.8 (30.7)	134.4 (28.9)	+2.7 (14.2)
Median (min, max)	134.5 (60, 202)	145.0 (70, 206)	10.5 (70, 206)	137.5 (85, 199)	135.5 (85, 210)	2.0 (−28, 34)
^a p = 0.00068 versus baseline, 2‐tailed Student's t‐tests for correlated samples. ^b p < 0.05.
Posterior terminal hair counts
Mean (SD)	167.1 (32.9)	179.2 (34.0)	+12.1 (18.7)^a,b	175.2 (34.6)	175.6 (31.7)	+0.6 (18.6)
Median (min, max)	168 (100, 233)	183 (105, 258)	12 (−20, 41)	175 (123, 246)	172 (117, 232)	3 (−39, 31)
^a p < 0.0005 versus baseline, 2‐tailed Student's t‐test for correlated samples. ^b p < 0.05 versus placebo, 2‐tailed Student's t‐test for independent samples.
Anterior vellus hair counts
Mean (SD)	10.8 (9.5)	15.2 (12.6)	+4.4 (9.2)^a,b	14.9 (10.9)	12.2 (11.4)	−2.7 (10.7)
Median (min, max)	8 (0, 37)	11 (0, 50)	3.5 (−11, 28)	14 (0, 35)	8.5 (0, 41)	−1.5 (−32, 11)
^a p < 0.0005 versus baseline, 2‐tailed Student's t‐test for correlated samples. ^b p < 0.01 versus placebo, 2‐tailed Student's t‐test for independent samples.
Posterior vellus hair counts
Mean (SD)	4.8 (6.6)	5.8 (6.9)	+1.0 (8.0)	3.5 (3.1)	5.4 (4.7)	+1.9 (4.2)
Median (min, max)	1 (0, 29)	3 (0, 31)	0 (−22, 20)	3 (0, 11)	4.5 (0, 14)	0 (−6, 10)
Anterior total hair counts
Mean (SD)	143.7 (28.0)	159.4 (30.7)	+15.7 (18.5)^a,b	146.7 (33.3)	146.6 (27.4)	−0.1 (19.8)
Median (min, max)	146.5 (66, 206)	155.5 (97, 219)	13.5 (−31, 52)	142 (98, 222)	139.5 (101, 213)	−1 (−36, 39)
^a p = NS versus baseline, 2‐tailed Student's t‐test for correlated samples. ^b p < 0.005 versus placebo, 2‐tailed Student's t‐test for independent samples.
Posterior total hair counts
Mean (SD)	171.9 (35.4)	185.0 (36.0)	+13.10 (21.4)^a,b	178.7 (33.3)	181.0 (30.2)	+2.3 (18.5)
Median (min, max)	171 (100, 246)	190 (105, 272)	11 (−42, 58)	178 (130, 249)	174.5 (127, 232)	3 (−31, 39)
^a p = 0.0004 versus baseline, 2‐tailed Student's t‐test for correlated samples. ^b p < 0.05 versus placebo, 2‐tailed Student's t‐test for independent samples.

TABLE 3

	Day 0	Day 90	Change	Day 0	Day 90	Change
	Anterior terminal hair counts			Posterior terminal hair counts
Mean (SD)	128.6 (23.76)	138.6 (29.45)	+10 (15.27)^a	185.87 (23.98)	191.8 (27.49)	+5.93 (19.45)
Median (min, max)	128 (82, 169)	142 (90, 206)	8 (−15, 37)	194 (142, 220)	193 (146, 258)	6 (−20, 39)
^a p < 0.05 versus baseline, 2‐tailed Student's t‐tests for correlated samples.
	Anterior vellus hair counts			Posterior vellus hair counts
Mean (SD)	13.6 (9.88)	19.47 (15.59)	+5.87 (11.46)	5.47 (8.88)	6.00 (5.98)	+0.53 (9.28)
Median (min, max)	12 (0, 37)	20 (0, 50)	6 (−11, 28)	0 (0, 29)	6 (0, 15)	0 (−22, 15)
	Anterior total hair counts			Posterior total hair counts
Mean (SD)	142.2 (23.15)	158.07 (28.15)	+15.87 (16.77)^a	191.33 (28.95)	197.8 (29.5)	+6.47 (22.47)
Median (min, max)	145 (96, 178)	155 (110, 206)	13 (−11, 52)	194 (142, 238)	196 (146, 272)	10 (−42, 39)
^a p < 0.005 versus baseline, 2‐tailed Student's t‐test for correlated samples.

TABLE 4

	Active (n = 40)			Placebo (n = 20)
	Day 0	Day 90	Change	Day 0	Day 90	Change
Total number of hairs (summed across all regions), n (%)
Mean (SD)	1.2 (1.0)	0.8 (0.9)	−0.4 (1.1)^a	1.1 (1.3) 1.0 (0.9)	1.0 (0.9)	−0.2 (1.3)
Median (min, max)	1 (0, 3)	1 (0, 3)	0 (−3, 2)	1 (0, 4)	1 (0, 4)	0 (−3, 4)
^a p < 0.05 versus baseline, 2‐tailed Student's t‐test for correlated samples
Number of hairs: vertex, n (%)
Mean (SD)	0.5 (0.6)	0.3 (0.6)	−0.2 (0.7)	0.8 (0.8)	0.4 (0.6)	−0.4 (0.9)
Median (min, max)	0 (0, 2)	0 (0, 2)	0 (−2, 1)	1 (0, 3)	0 (0, 2)	0 (−2, 2)
Number of hair: left parietal, n (%)
Mean (SD)	0.2 (0.5)	0.1 (0.2)	−0.1 (0.5)	0.1 (0.3)	0.1 (0.2)	−0.1 (0.2)
Median (min, max)	0 (0, 2)	0 (0, 1)	0 (−1, 1)	0 (0, 1)	0 (0, 1)	0 (−1, 0)
Number of hairs: right parietal, n (%)
Mean (SD)	0.2 (0.4)	0.1 (0.3)	−0.1 (0.6)	0.2 (0.4)	0.3 (0.4)	0.1 (0.6)
Median (min, max)	0 (0, 1)	0 (0, 1)	0 (−1, 1)	0 (0, 1)	0 (0, 1)	0 (−1, 0)
Number of hairs: occipital, n (%)
Mean (SD)	0.4 (0.7)	0.3 (0.5)	−0.1 (0.7)	0.3 (0.7)	0.3 (0.4)	−0.1 (0.9)
Median (min, max)	0 (0, 3)	0 (0, 2)	0 (−2, 1)	0 (0, 3)	0 (0, 1)	0 (−3, 1)

TABLE 5

Rating n (%)	Active (n = 40)	Placebo (n = 20)
Hair quality
Greatly improved	1 (2.5)	—
Moderately improved	10 (25)	4 (20)
Slightly improved	21 (52.5)	6 (30)
No change	3 (7.5)	7 (35)
Slightly worsened	5 (12.5)	3 (15)
Moderately worsened	—	—
Greatly worsened	—	—
Hair growth
Greatly increased	—	—
Moderately increased	9 (23)	2 (10)
Slightly increased	15 (38)	4 (20)
No change	9 (23)	9 (45)
Slightly decreased	7 (18)	5 (25)
Moderately decreased	—	—
Greatly decreased	—	—

References

Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled
Untitled

Used In Evidence Reviews

B Saw Palmetto لـ تساقط الشعر النمطي الأنثوي

The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results.

Embed This Widget

Study Design

Abstract

Full Text

Figures

Tables

References

Used In Evidence Reviews

Similar Papers

A review of the treatment of male pattern hair loss.

An overview of herbal alternatives in androgenetic alopecia.

Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.

Herbal preparations for the treatment of hair loss.

Natural products for male androgenetic alopecia.

Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract.